Updated May 2026 · ClinicalTrials.gov

RECRUITINGPhase 2INTERVENTIONAL

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Precision Medicine Applied to Locally Advanced Thyroid Cancer Using Tumor-derived Organoids and In-vitro Sensitivity Testing: a Phase 2a, Single-center, Open-label, and Non-comparative Study

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer (NCT06482086) is a Phase 2 interventional studying Locally Advanced Thyroid Gland Carcinoma, sponsored by West China Hospital. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

What Stage of Research Is This?

Phase 2 trials evaluate whether a treatment actually works against Locally Advanced Thyroid Gland Carcinoma and continue monitoring side effects. Phase 2 enrolls larger groups (typically 100–300 patients) and produces the first real efficacy signal. A successful Phase 2 readout is what unlocks the much larger Phase 3 confirmatory trials needed for FDA approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

Target enrollment of 75 participants puts this in the typical range for a Phase 2-style efficacy study or a moderate Phase 3 trial in a focused Locally Advanced Thyroid Gland Carcinoma subpopulation. At this scale, the study has enough statistical power to detect a clear treatment effect but is not the largest cohort in the field.

Who May Be Eligible (Plain English)

Who May Qualify: - 1\. Adult participants who have either been initially diagnosed with locally advanced thyroid cancer or have experienced persistent or recurrent thyroid cancer, including cervical nodal recurrence. Types of pathology include: 1. Papillary thyroid carcinoma (PTC) 2. Follicular thyroid carcinoma (FTC) 3. Medullary thyroid carcinoma (MTC) 4. Poorly differentiated thyroid carcinoma (PDTC) 5. Anaplastic thyroid carcinoma (ATC) - 2\. Evidence of extrathyroidal extension and/or locally invasive disease and deemed at risk for R2 resection by treating team on clinical and/or fiberoptic examination and/or radiographic evaluation in the primary or recurrent setting. Evidence of "at risk for R2 resection" includes: 1. Vocal cord paralysis by fiberoptic examination 2. Extrathyroid and/or extranodal extension on CT or MRI, including tracheal and/or laryngeal cartilage invasion, esophageal involvement, and/or involvement of perithyroid muscles (e.g. strap, sternocleidomastoid, inferior constrictor muscles) or bone involvement 3. Extension into the mediastinum with visceral and/or vascular involvement 4. Involvement of the carotid artery or other major vessel by 180 degrees or more 5. Other factors that make the participant to be "at risk for R2 resection" may be allowed, after discussion with the study's principal investigator. - 3\. There is at least one measurable lesion according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST). - 4\. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2. - 5\. Normal organ and bone marrow function. - 6\. Adequate end-organ function (including bone marrow, coagulation, renal, liver and cardiac) 28 days prior to the study registration. - 7\. Ability to swallow pills. - 8\. Signed willing to sign a consent form form. - 9\. Expected survival time of more than 2 months. Who Should NOT Join This Trial: ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * 1\. Adult participants who have either been initially diagnosed with locally advanced thyroid cancer or have experienced persistent or recurrent thyroid cancer, including cervical nodal recurrence. Types of pathology include: 1. Papillary thyroid carcinoma (PTC) 2. Follicular thyroid carcinoma (FTC) 3. Medullary thyroid carcinoma (MTC) 4. Poorly differentiated thyroid carcinoma (PDTC) 5. Anaplastic thyroid carcinoma (ATC) * 2\. Evidence of extrathyroidal extension and/or locally invasive disease and deemed at risk for R2 resection by treating team on clinical and/or fiberoptic examination and/or radiographic evaluation in the primary or recurrent setting. Evidence of "at risk for R2 resection" includes: 1. Vocal cord paralysis by fiberoptic examination 2. Extrathyroid and/or extranodal extension on CT or MRI, including tracheal and/or laryngeal cartilage invasion, esophageal involvement, and/or involvement of perithyroid muscles (e.g. strap, sternocleidomastoid, inferior constrictor muscles) or bone involvement 3. Extension into the mediastinum with visceral and/or vascular involvement 4. Involvement of the carotid artery or other major vessel by 180 degrees or more 5. Other factors that make the participant to be "at risk for R2 resection" may be allowed, after discussion with the study's principal investigator. * 3\. There is at least one measurable lesion according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST). * 4\. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2. * 5\. Normal organ and bone marrow function. * 6\. Adequate end-organ function (including bone marrow, coagulation, renal, liver and cardiac) 28 days prior to the study registration. * 7\. Ability to swallow pills. * 8\. Signed informed consent form. * 9\. Expected survival time of more than 2 months. Exclusion Criteria: * 1\. Patients with contraindications specified in the drug instructions for the targeted drugs involved in the corresponding organoid drug sensitivity tests. * 2\. Patients with incomplete clinical data. * 3\. Patients with severe organ dysfunction, metabolic diseases, or other conditions significantly affecting survival. * 4\. Other active malignant disease requiring therapy. * 5\. Females who are pregnant or breastfeeding. * 5\. Patients without target lesions. * 6\. Patients deemed unsuitable for inclusion by the researchers.

Treatments Being Tested

DRUG

Anlotinib

8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.

DRUG

Lenvatinib

8/12 mg qd, po.

DRUG

Sorafenib

0.4 g bid, po.

DRUG

Donafenib

0.3 g bid, po.

DRUG

Everolimus

10 mg qd, po.

DRUG

Apatinib

500 mg qd, po.

DRUG

Dabrafenib + Trametinib

Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.

DRUG

Cabozantinib

Cabozantinib 60mg qd, po.

DRUG

Vandetanib

Vandetanib 300mg qd, po.

DRUG

Entrectinib

Entrectinib 600mg qd，po.

DRUG

Pralsetinib

400mg qd, po.

DRUG

Larotrectinib

100mg qd，po

Locations (1)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

West China hospital

Chengdu, Sichuan, China

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT06482086), the sponsor (West China Hospital), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT06482086 clinical trial studying?

The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced thyroid cancer who have undergone conventional therapy in the past or unresectable patients . The full protocol is registered on ClinicalTrials.gov and includes the primary outcome measures, eligibility criteria, and study endpoints.

Who can participate in NCT06482086?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT06482086?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT06482086. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT06482086. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.